Gene Expression Research

The latest news about RNA-seq, gene expression profiling, and transcriptome sequencing.

NanoString Technologies this week provided investors with a mixed bag of news as it released its second quarter earnings and financial outlook for the rest of the year.

Ascendas will develop and commercialize molecular diagnostic systems and assays using certain of Fluidigm's microfluidic technologies.

New data now suggests that evaluating PD-L2 levels might better predict response to PD-1 targeting immune-oncology drugs than current tests that only measure PD-L1.

The firm expects full-year revenue growth of up to 39 percent, but fell short of prior guidance for the year.